PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression
Open Access
- 22 July 2024
- journal article
- research article
- Published by Springer Nature in Genome Medicine
- Vol. 16 (1) , 1-21
Abstract
Background: The identification of cancer driver genes from sequencing data has been crucial in deepening our understanding of tumor biology and expanding targeted therapy options. However, apart from the most commonly altered genes, the mechanisms underlying the contribution of other mutations to cancer acquisition remain understudied. Leveraging on our whole-exome sequencing of the largest Asian lung adenocarcinoma (LUAD) cohort (n = 302), we now functionally assess the mechanistic role of a novel driver, PARP4.Methods: In vitro and in vivo tumorigenicity assays were used to study the functional effects of PARP4 loss and mutation in multiple lung cancer cell lines. Interactomics analysis by quantitative mass spectrometry was conducted to identify PARP4’s interaction partners. Transcriptomic data from cell lines and patient tumors were used to investigate splicing alterations.Results: PARP4 depletion or mutation (I1039T) promotes the tumorigenicity of KRAS- or EGFR-driven lung cancer cells. Disruption of the vault complex, with which PARP4 is commonly associated, did not alter tumorigenicity, indicating that PARP4’s tumor suppressive activity is mediated independently. The splicing regulator hnRNPM is a potentially novel PARP4 interaction partner, the loss of which likewise promotes tumor formation. hnRNPM loss results in splicing perturbations, with a propensity for dysregulated intronic splicing that was similarly observed in PARP4 knockdown cells and in LUAD cohort patients with PARP4 copy number loss.Conclusions: PARP4 is a novel modulator of lung adenocarcinoma, where its tumor suppressive activity is mediated not through the vault complex—unlike conventionally thought, but in association with its novel interaction partner hnRNPM, thus suggesting a role for splicing dysregulation in LUAD tumorigenesis.Keywords
Funding Information
- National Medical Research Council (NMRC/OFLCG/002-2018, NMRC/OFIRG/0064/2017, OFIRG19nov-0106, OFIRG21nov-0068)
- National Research Foundation Singapore (NRF-NRFF2015-04, NRF-NRFI08-2022)
This publication has 99 references indexed in Scilit:
- HnRNPM is a potential mediator of YY1 which promotes EMT in prostate cancer cellsThe Prostate, 2019
- Assessment of PARP4 as a candidate breast cancer susceptibility geneBreast Cancer Research and Treatment, 2019
- Expansion of airway basal epithelial cells from primary human non‐small cell lung cancer tumorsInternational Journal of Cancer, 2018
- The hnRNP family: insights into their role in health and diseaseHuman Genetics, 2016
- A gene-alteration profile of human lung cancer cell linesHuman Mutation, 2009
- Movement of vault particles visualized by GFP-tagged major vault proteinCell and tissue research, 2006
- AMBER force-field parameters for phosphorylated amino acids in different protonation states: phosphoserine, phosphothreonine, phosphotyrosine, and phosphohistidineJournal of Molecular Modeling, 2005
- The vault complexCellular and Molecular Life Sciences, 2003
- Sequence and structure-based prediction of eukaryotic protein phosphorylation sitesJournal of Molecular Biology, 1999
- Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water modelsJournal of Computational Chemistry, 1992